Medicine
Bupropion Hydrochloride XL 150 mg extended-release tablet
Bupropion Hydrochloride XL 150 mg extended-release tablet is a prescription medicine containing Bupropion for oral use, marketed by Actavis Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Bupropion
- Brand
- Bupropion Hydrochloride XL
- Strength
- 150 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 500 tablets, 90 tablets, 30 tablets and 11 more
- Marketing authorisation holder
- Actavis Pharma
- Manufacturers
- Actavis PharmaAsclemedA-S Medication SolutionsProficient Rx
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AX12 Bupropion
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 26 November 2008
- Identifiers
- RxCUI 993541DailyMed set ID ec9cbb38-1582-492f-a526-4b3675c55b14, 9d08b4ae-077d-4cd8-9ca4-8d5cd63f400b, a1e768fd-c28f-4b49-822d-ccc315b4099c +1NDC 63187-766, 50090-4049, 0591-3331 +1Application ANDA077715
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 500 tablet, film coated, extended release in 1 bottle, plastic | 0591-3331-05 | Actavis Pharma | 26 November 2008 |
| 90 tablet, film coated, extended release in 1 bottle, plastic | 0591-3331-19 | Actavis Pharma | 26 November 2008 |
| 30 tablet, film coated, extended release in 1 bottle, plastic | 0591-3331-30 | Actavis Pharma | 26 November 2008 |
| 90 tablet, film coated, extended release in 1 bottle | 50090-4049-0 | A-S Medication Solutions | 11 January 2019 |
| 30 tablet, film coated, extended release in 1 bottle | 50090-4049-1 | A-S Medication Solutions | 11 January 2019 |
| 60 tablet, film coated, extended release in 1 bottle | 50090-4049-2 | A-S Medication Solutions | 11 January 2019 |
| 100 tablet, film coated, extended release in 1 bottle, plastic | 76420-923-01 | Asclemed | 25 February 2025 |
| 500 tablet, film coated, extended release in 1 bottle, plastic | 76420-923-05 | Asclemed | 25 February 2025 |
| 30 tablet, film coated, extended release in 1 bottle, plastic | 76420-923-30 | Asclemed | 25 February 2025 |
| 60 tablet, film coated, extended release in 1 bottle, plastic | 76420-923-60 | Asclemed | 25 February 2025 |
| 90 tablet, film coated, extended release in 1 bottle, plastic | 76420-923-90 | Asclemed | 25 February 2025 |
| 30 tablet, film coated, extended release in 1 bottle, plastic | 63187-766-30 | Proficient Rx | 1 November 2016 |
| 60 tablet, film coated, extended release in 1 bottle, plastic | 63187-766-60 | Proficient Rx | 1 November 2016 |
| 90 tablet, film coated, extended release in 1 bottle, plastic | 63187-766-90 | Proficient Rx | 1 November 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 December 1985 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Bupropion 150 mg extended-release tablet.
- Bupropion 150 mg extended-release tabletAvailable on request—US FDA40 packs
- Bupropion Hydrochloride (XL) 150 mg extended-release tabletAvailable on requestScieGen PharmaceuticalsUS FDA17 packs
- Bupropion Hydrochloride XL 150 mg extended-release tabletAvailable on requestEpic PharmaUS FDA19 packs
- Bupropion Hydrochloride XL 150 mg extended-release tabletAvailable on requestLupinIndiaUS FDA12 packs
- Bupropion hydrochloride (XL) 150 mg extended-release tabletAvailable on requestLannettUS FDA12 packs
- Bupropion Hydrochloride (XL) 150 mg extended-release tabletAvailable on requestCiplaIndiaUS FDA6 packs
Other strengths and forms of Bupropion
Clinical summary
Bupropion is an aminoketone indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Bupropion for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BupropionFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- WELLBUTRIN SR prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
Need Bupropion Hydrochloride XL 150 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.